spacer
home > epc > autumn 2003 > clinical trials in asthma
PUBLICATIONS
European Pharmaceutical Contractor

Clinical Trials in Asthma

Respiratory physicians are buzzing about the number of new asthma drugs being developed by a variety of pharmaceutical companies. This is good news for approximately 155 million people worldwide who are affected by the disease. The prevalence of asthma is increasing, generally thought to be associated with spreading urbanisation and exposure to respiratory toxins - including domestic mites, vehicle exhaust and passive smoking.

Asthma is caused by both host risk factors and environmental risk factors. Host factors include genetic predisposition, atopy, airway hyper-responsiveness, gender, race and ethnicity. Environmental factors which increase susceptibility include indoor and outdoor allergens, tobacco smoke, air pollution, respiratory infections - especially viral disease, family size, diet, drugs, obesity and family pets. Recently there has been much research into asthma but the balance between nature, nurture and the changing environment remains poorly understood. We have a long way to go, but there are the beginnings of new therapies for asthma which offer hope for the future.


Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
By Dr Alan Davies, Therapeutic Director for Kendle International Inc

Dr Alan Davies qualified at the London Hospital Medical College, obtaining an MB BS in 1975 and an MRCP in 1979. Dr Davies has more than 20 years' experience in drug and device development. He has worked as a University Lecturer in the Medical Schools of Adelaide in Australia, and Manchester and Bristol in the UK. He was awarded an MD in 1988 for his original work on microvascular disease and glycaemic control in children with insulin-dependant diabetes mellitus. Dr Davies joined Novo Laboratories in 1988 and became Head of Clinical Research for Fujisawa GmbH, Munich in the 1990s. Since 2000 he has been Therapeutic Director for Kendle International Inc, one of the world's largest contract research organisations.

spacer
Dr Alan Davies
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Meet SHL at Pharmapack Europe 2020

SHL will exhibit at Pharmapack Europe 2020 between February 5-6 in Paris, France. In addition to showcasing our key services and products, Business Development Director Markus Bauss will give a talk in the Connectivity and Patient-Centricity conference session on February 5.
More info >>

White Papers

Autoinjector testing made safe efficient and flexible

ZwickRoell

The autoinjector market is one of the fastest growing markets across almost all pharmaceutical applications. Studies expect a global market volume of approximately USD 2.5 billion by 2020, with pre-filled autoinjectors representing the largest market segment. There are a variety of tests that can be performed on autoinjectors, and these are well-demonstrated by the Zwick product portfolio. The Ulm-based company and specialist in testing systems offers a variety of testing systems that are already being successfully used by multiple pharmaceutical companies.
More info >>

 
Industry Events

2020 Avoca Quality and Innovation Summit

3-4 June 2020, Amsterdam, The Netherlands

The 2020 Avoca Quality and Innovation Summit will take place 3-4 June 2020, in Amsterdam, The Netherlands.
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement